PHAT Q4 2025 Earnings — Phathom Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

PHATPhathom Pharmaceuticals, Inc.

$891M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+94.1% YoY

Gross Profit

$50M86.7% margin

Operating Income

-$6M-10.3% margin

Net Income

-$21M-36.7% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+16.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$259M

Total Liabilities

$697M

Stockholders' Equity

-$438M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$30M	+94.1%
Gross Profit	$50M	$26M	+93.2%
Operating Income	-$6M	-$59M	+90.0%
Net Income	-$21M	-$74M	+71.6%